Interview with Dmitri Pavlovich, MD, Director, Clinical Operations Russia,…
The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and…
Address: Quintiles GesmbH, Leningradskiy prospekt 37A, bldg. 14, floor 4, 125167 Moscow, Office complex ARCUS,Russia
Tel: + 7 495 721 1964
Web: http://www.quintiles.com/locations/europe/Russia/
• Quintiles started operations in Russia in 1996
• First office opened in Moscow in 1997;
• Office in St. Petersburg opened in 2005;
• Office in Novosibirsk, centre of Siberian region of Russia, opened in 2007.
• 226 professional employees in total (119 in Moscow, 89 in St. Petersburg, 18 in Novosibirsk);
• Russia has centralized medical care system, common standards across the country, qualified and experienced investigators;
• 93% of staff has an university degree. Within clinical staff 56% of employees have MD degree;
• Quintiles Russia provides wide range of services including site ID and feasibility, SSU together with RA, clinical monitoring, GFR, PCC. Starting from 2010 we began our expansion in commercialization;
• Quintiles has well established relationship with regulatory bodies and also key opinion leaders across the country – which allows representation in all regions of Russia and Quintiles appears to be the leading CRO in Russia, based on the number of initial trial submissions during the year.
• Key drivers of clinical trial market in the country – governmental focus on innovative technologies including pharmaceutical industry, continued growth and further high potential of clinical research market in Russia
• Key advantages – strong and long-term Quintiles experience on country level, common medical standards and practices across the country, direct access to a network of high professional sites and investigators, high recruitment potential in wide range of indications including naïve patients, centralized submission/approval process
• Clinical services
• Commercial services
• Consulting
• Capital (investment)
The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and…
The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations…
The latest news from Russian pharma, including Biocad’s ramping up of Sputnik V COVID-19 vaccine manufacturing,…
The latest news from Russian pharma and healthcare including a big funding injection for primary care up to 2025,…
Russia has announced that a domestically developed COVID-19 vaccine has been approved by its health authorities,…
Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in…
Russia is facing a drug shortage crisis which is having a particular impact on patients with life-threatening…
In the latest twist in the ongoing story of Russian interference in the US presidential elections of 2016, it has…
In the United States, Johnson & Johnson has an image of being very close to people. Americans grow up with this…
You took over this organization just three months ago, having previously headed businesses in industries as diverse…
The ARPM was founded in 2002, and you were its director from 2002-2004, before leaving for a post at the…
When Focus Reports prepared a report on the French pharmaceutical industry in 2009/10, we found that the head of…
The U.S. and Russia have a long history of trade, and you have personally been with the American Chamber of…
The primary objectives of this association are to promote Russia as a clinical trial destination, optimize the…